Venus Remedies
VENUSREMNSE

Venus Remedies

₹1,768.1076.20 (4.50%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
1,630.00
Today’s high
1,776.20
52 week low
416.00
52 week high
1,943.80
Open price
1,694.20
Previous close
1,691.90
Live volume
84,027
Lower circuit
1,679.70
Upper circuit
1,856.50

Fundamentals

Market Cap
₹2,267Cr
ROE
15.49%
P/E Ratio(TTM)
22.05
EPS(TTM)
76.90
P/B Ratio
3.42
Dividend Yield
0.59%
Industry P/E
34.37
Book Value
496.56
Debt to Equity
0.02
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹264
+44.63%
Profit (Cr)
₹47.50
+85.69%
075150225300
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+31%
3Y CAGR+3%
Profit growthValue
1Y (TTM)+126%
3Y CAGR+4%

About

Venus Remedies Limited is a research-driven Indian pharmaceutical company with a global presence, specializing in the injectables space. The company's core vision is to leave a positive footprint on human health by creating an institution that transcends the mortal being. A key part of its Mission 2026 is to foster innovative therapies that target the major health challenge of Antimicrobial Resistance. It develops solutions for human ailments in critical areas like oncology, neurology, pain management, and also has a herbal product portfolio. The company's priority regions are the Middle East, South-East Asia, Africa, and Latin America, where it aims to be a partner of choice. With over 1040 marketing authorisations and more than 25 GMP approvals, the company has expanded its boundaries to over 90 countries.;
CEO/MD
Pawan Chaudhary
Founded in
1989
NSE symbol
VENUSREM

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Retail And Others
54.24%
Promoters
41.76%
Foreign Institutions
2.80%
Other Domestic Institutions
1.20%

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹8,513.00
-56.50 (0.66%)
L
    H
    21,391.38114.0724.51
    PfizerPFIZER
    ₹4,497.00
    +33.70 (0.76%)
    L
      H
      20,446.9528.34.86
      ₹1,461.00
      +24.40 (1.70%)
      L
        H
        19,867.0830.685.09
        ₹788.00
        +9.60 (1.23%)
        L
          H
          19,290.9932.423.79
          Livesquawk
          Venus Remedies Q4 EBITDA rose to ₹634M from ₹290M YoY. EBITDA margin expanded to 24.4% from 14.9% YoY.
          2026
          26
          May
          Annual Result
          Release date
          29
          Jan
          Quarterly Result
          Release date
          2025
          10
          Nov
          Quarterly Result
          Release date
          1
          Aug
          Quarterly Result
          Release date
          Events calendar
          View upcoming events in other stocks